Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this article, we are going to take a look at where Bristol-Myers Squibb Company ...
He also emphasized the U.S. approval and strong initial launch of Cobenfy, noted as the first novel mechanism for schizophrenia treatment in decades. Financial discipline remained a priority ...
Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...
The Standard's journalism is supported by our readers. When you purchase through links on our site, we may earn an affiliate commission. The world of content creation is vast and constantly ...
The top 10 biopharma M&A deals of 2023 The company is counting heavily on Cobenfy, which was approved in September and was the crown jewel of the $14 billion buyout of Karuna. BMS reported sales ...
Fortnite's February 2025 Crew Pack features Haruka of the Masks outfit,new back bling, and pickaxe. Fans excited for Japanese-themed skin. January's Crew Pack had mixed reviews, but February's ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
He has mentioned the firm multiple times in 2025, and most of his comments have focused on Bristol-Myers Squibb Company (NYSE:BMY)’s schizophrenia drug Cobenfy. The stock is up by 18% over the ...
(Pediatric Research) Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease psychosis, agitation, and cognition? Bristol Myers ...
We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ...
Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential
David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback